Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

Blood blood.2025031449.

https://doi.org/10.1182/blood.2025031449

Published: 2025

Includes: Supplemental data

Journal Articles

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Blood (2025) 146 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2025-LBA-2

Published: 2025

Journal Articles

Efficacy of mitapivat in patients with transfusion-dependent alpha-thalassemia: Subgroup analysis from the ENERGIZE-T trial

Blood (2025) 146 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2025-4699

Published: 2025

Journal Articles

Ianalumab retreatment in adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who benefitted from previous ianalumab treatment: A phase 2 exploratory study

Francesco Zaja, Adam Cuker, Hanny Al-Samkari, Marc Michel, Yogesh Chattar, Matthew Foster, Meritxell Vendranas, Nicola Cooper

Blood (2025) 146 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2025-6586

Published: 2025

Journal Articles

Characterization of platelet autoantibody prevalence, serology, and predictive value for progression to immune thrombocytopenia in patients with persistent isolated mild thrombocytopenia (PIMT)

Ellen Zhang, Rebecca Leaf, Debbie Jiang, Katayoon Goodarzi, David Kuter, Hanny Al-Samkari

Blood (2025) 146 (Supplement 1): 1266.

https://doi.org/10.1182/blood-2025-1266

Published: 2025

Journal Articles

Clinical spectrum of hereditary hemorrhagic telangiectasia (HHT): Data from the comprehensive hht outcomes registry of the United States (CHORUS)

Blood (2025) 146 (Supplement 1): 309.

https://doi.org/10.1182/blood-2025-309

Published: 2025

Journal Articles

Long-term safety and effectiveness of systemic bevacizumab for chronic severe bleeding in idiopathic gastrointestinal angiodysplasia, esophageal varices, and angiodysplasia of von willebrand disease and acquired von willebrand syndrome

Nardeen Ayad, Hanny Al-Samkari

Blood (2025) 146 (Supplement 1): 307.

https://doi.org/10.1182/blood-2025-307

Published: 2025

Journal Articles

An interim assessment of bleeding events in a prospective natural history study of hereditary hemorrhagic telangiectasia patients using a validated bleeding scale and a novel daily reporting instrument

John Lee, Aysheh Alrfooh, Lynn Gallant, Cassi Friday, Sandra Teixeira, Jean-Christophe Hus, Scott Olitsky, Hanny Al-Samkari

Blood (2025) 146 (Supplement 1): 2702.

https://doi.org/10.1182/blood-2025-2702

Published: 2025

Journal Articles

Overall survival (OS) in patients with metastatic colorectal cancer (mCRC) following persistent chemotherapy-induced thrombocytopenia (pCIT)

Ju-Hyeun Kim, Scott Stryker, Peter Enzinger, Hanny Al-Samkari

Blood (2025) 146 (Supplement 1): 2681.

https://doi.org/10.1182/blood-2025-2681

Published: 2025

Journal Articles

Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)

Monica Carpenedo, Catherine Broome, Blanca Sánchez González, Vickie McDonald, Yoshitaka Miyakawa, Kaichi Nishiwaki, Francesco Zaja, Hanny Al-Samkari, Filip Matthijssens, Damien Chimits, Jaume Ayguasanosa, Syed Raza, Giles Monnickendam, Francesco Rodeghiero, Marc Michel, Adrian Newland

Blood (2025) 146 (Supplement 1): 6245.

https://doi.org/10.1182/blood-2025-6245

Published: 2025

Journal Articles

Development of a prediction model for maternal pregnancy complications in sickle cell disease

Aaron Cheng, Phyllis Gimotty, David Margolis, Scott Peslak, Hanny Al-Samkari, Andrea Roe, Janet Kwiatkowski

Blood (2025) 146 (Supplement 1): 1091.

https://doi.org/10.1182/blood-2025-1091

Published: 2025

Journal Articles

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

Blood (2025) 146 (Supplement 1): 841.

https://doi.org/10.1182/blood-2025-841

Published: 2025

Journal Articles

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Mikkael A. Sekeres, Hanny Al-Samkari, Hetty E. Carraway, Amy E. DeZern, Moshe Mittelman, Meredith Little, Vanessa Beynon, Xiaoshu Dai, Sal Sommakia, Jenny M. Despotovic, Parija Patel, Melissa Dibacco, Bruno Fattizzo, Eytan M. Stein, David Sallman, Austin G. Kulasekararaj, Uwe Platzbecker, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 6708.

https://doi.org/10.1182/blood-2024-203073

Published: 2024

Journal Articles

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Hanny Al-Samkari, Vickie McDonald, Monica Carpenedo, Francesco Zaja, Nichola Cooper, Spero Cataland, Michael W Drazer, Yoshitaka Miyakawa, Marc Michel, Jaume Ayguasanosa, Janki Brahmbhatt, Lan Lan, Filip Matthijssens, Catherine M. Broome, Waleed Ghanima

Blood (2024) 144 (Supplement 1): 2570.1.

https://doi.org/10.1182/blood-2024-194816

Published: 2024

Journal Articles

Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease

Julia Z Xu, Enrico M Novelli, Jean-Antoine Ribeil, Andreas Glenthøj, Srila Gopal, Hanny Al-Samkari, Modupe Idowu, Jenny Despotovic, Spurthi Patil, Xiaoshu Dai, Abdullah Al Masud, Michael Callaghan, Fuad El Rassi

Blood (2024) 144 (Supplement 1): 2496.

https://doi.org/10.1182/blood-2024-203509

Published: 2024

Journal Articles

ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Blood (2024) 144 (Supplement 1): 409.

https://doi.org/10.1182/blood-2024-200867

Published: 2024

Journal Articles

Risk Factors for Bleeding after Recent Medical Hospitalization: The Medical Inpatient Thrombosis and Hemostasis Study (MITH)

Mansour Gergi, Katherine Wilkinson, Andrew Sparks, Nicholas S Roetker, Hanny Al-Samkari, Nicholas L Smith, Timothy B Plante, Mary Cushman, Allen B Repp, Chris E. Holmes, Karlyn A. Martin, Neil Zakai

Blood (2024) 144 (Supplement 1): 2252.

https://doi.org/10.1182/blood-2024-201581

Published: 2024

Journal Articles

Direct Glycoprotein-Specific Platelet Autoantibodies Detected in a Majority of Patients with Chemotherapy-Induced Thrombocytopenia

Andrew B Song, Brian Curtis, Hanny Al-Samkari

Blood (2024) 144 (Supplement 1): 1180.

https://doi.org/10.1182/blood-2024-194752

Published: 2024

Journal Articles

Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results

Alexander Röth, Wilma Barcellini, Christine Ademokun, Shripad Chitnis, Sofiya Matviykiv, Alessandra Vitaliti, Chi Chen, Vasiliki Katsanou, Raghav Chawla, Hanny Al-Samkari

Blood (2024) 144 (Supplement 1): 2457.

https://doi.org/10.1182/blood-2024-199637

Published: 2024

Journal Articles

Long-Term Safety and Effectiveness of Pomalidomide for Bleeding in Hereditary Hemorrhagic Telangiectasia

Ellen Zhang, Pamela G Hodges, Josanna Rodriguez-Lopez, Hanny Al-Samkari

Blood (2024) 144 (Supplement 1): 558.

https://doi.org/10.1182/blood-2024-202284

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Efficacy of mitapivat in patients with transfusion-dependent alpha-thalassemia: Subgroup analysis from the ENERGIZE-T trial

Ianalumab retreatment in adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who benefitted from previous ianalumab treatment: A phase 2 exploratory study

Characterization of platelet autoantibody prevalence, serology, and predictive value for progression to immune thrombocytopenia in patients with persistent isolated mild thrombocytopenia (PIMT)

Clinical spectrum of hereditary hemorrhagic telangiectasia (HHT): Data from the comprehensive hht outcomes registry of the United States (CHORUS)

Long-term safety and effectiveness of systemic bevacizumab for chronic severe bleeding in idiopathic gastrointestinal angiodysplasia, esophageal varices, and angiodysplasia of von willebrand disease and acquired von willebrand syndrome

An interim assessment of bleeding events in a prospective natural history study of hereditary hemorrhagic telangiectasia patients using a validated bleeding scale and a novel daily reporting instrument

Overall survival (OS) in patients with metastatic colorectal cancer (mCRC) following persistent chemotherapy-induced thrombocytopenia (pCIT)

Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)

Development of a prediction model for maternal pregnancy complications in sickle cell disease

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease

ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Risk Factors for Bleeding after Recent Medical Hospitalization: The Medical Inpatient Thrombosis and Hemostasis Study (MITH)

Direct Glycoprotein-Specific Platelet Autoantibodies Detected in a Majority of Patients with Chemotherapy-Induced Thrombocytopenia

Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results

Long-Term Safety and Effectiveness of Pomalidomide for Bleeding in Hereditary Hemorrhagic Telangiectasia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only